 |
市场调查报告书
商品编码
1190226
心臟安全服务市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)Cardiac Safety Service Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计心臟安全服务市场在预测期内（2022 年至 2027 年）的复合年增长率为 9%。
COVID-19 大流行给医疗保健行业带来了巨大压力，使其更加註重提供更好的医疗设施、监测设备、服务和远程会诊。 根据世界卫生组织 (WHO) 2020 年版，接受调查的国家中有一半以上 (53%) 部分或完全中断了高血压护理和 31% 的心血管急救服务。 COVID-19 的出现迫使政府和公司投入数十亿美元进行研发，以便为世界各地的患者带来更好的治疗、药物和服务。 例如，已发现 COVID-19 会增加所有类型心血管疾病的风险。 根据美国国家生物技术信息中心的数据，2021 年，在 COVID-19 患者中，急性心力衰竭 (3%-33%)、心肌缺血或梗塞 (0.9-11%)、心律失常 (9-17%)、等。观察到急性心脏病发展的证据。 在大流行期间，该国观察到的心血管死亡人数有所增加。 例如，根据美国心脏病学会的报告，纽约在大流行期间死于缺血性心脏病 (139%) 和高血压疾病 (164%) 的相对增幅最高。
心臟安全服务市场的增长主要是由于心血管疾病患病率上升以及人们对心臟问题和慢性心脏病的认识不断提高。 根据美国国家生物技术信息中心的数据，到 2021 年，全球将有约 6430 万人患有心力衰竭。 美国的心力衰竭患病率为 600 万，占总人口的 1.8%。 在加拿大，患病率在 1.5% 到 1.9% 之间，而在欧洲，美国心臟协会的一份报告估计 2021 年心力衰竭的患病率在 1% 到 2% 之间。 此外，医疗保健行业研发支出的增加和研发活动的外包也是推动市场增长的因素。 现代技术带来了帮助监测和改善心血管健康的解决方案。 例如，心脏病学和放射学仪器现在使用人工智能和机器来帮助定位潜在的心臟和血管问题，供心脏病专家检查。 由于人口中心血管疾病的增加，发达国家正趋向于增加对心臟安全服务的利用。
然而，巨大的服务成本和熟练工人的短缺可能会阻碍市场增长。
心臟安全服务的市场趋势
ECG Holter 测量服务领域主导市场
ECG Holter 测量服务预计将在预测期内主导市场。
该细分市场的增长主要是由于人口老龄化加剧和心血管疾病患病率上升。 Health System Tracker 2022 发布的数据证实，心脏病是美国的头号死因。 世界心臟联合会预测，到 2030 年，每年将有超过 2300 万例与 CVD 相关的死亡。 这些因素推动了对连续心率监测和即时心率检测设备的需求。 在过去的几年中，心电图监测设备已被用于医疗保健系统，以检测心臟功能异常。 随着技术的进步，新的 ECG Holter 测量设备正在推出。 Holter 监视器是一种便携式、电池供电的心电图设备，患者佩戴 24 至 48 小时，以连续记录心臟活动（心电图）并监测心跳。 与传统心电图仪相比，这种便携式心电图仪具有引线更少、患者在日常生活中可以自由活动等优点。 各种可穿戴心电图仪已进入市场，包括 Apple Watch、AliveCor 的 KardiaBand 和 Withings 的 ScanWatch，其中包括用于监测心臟健康的心电图传感器。 Apple Watch 4 及更高版本以及 AliveCor 的 Kardia 设备都经过美国食品和药物管理局的测试和批准，可以检测心房颤动，房颤会导致心力衰竭、中风甚至痴呆。
这些先进的 ECG-Holter 测量设备为心臟安全服务市场的增长提供了有利可图的机会。
北美主导市场，预计在预测期内也会如此
由于老年患者数量不断增加且心血管疾病患病率高，预计在预测期内北美将占心臟安全服务的主要份额。 美国心臟协会公布的数据（2020）发现，美国每年记录大约 605,000 例新发心脏病和 200,000 例復发性心脏病发作。 COVID-19 正在增加人们患心脏病的风险。 例如，接受 COVID-19 治疗的美国退伍军人在 12 个月后患心力衰竭的风险增加了 72%。 根据 2022 年版 Nature Medicine 发表的题为“Long Covid may worse heart disease risk”的数据，美国有 1.7% 的 Covid-19 患者患有心血管疾病或心律异常。研究发现，有 2.39% 的患者容易出现血管中形成血栓。
此外，先进的医疗保健系统、提高公众对心血管疾病预防而非治疗的认识、医疗保健运动以及政府对医疗保健系统的投资和服务交付都为该地区的市场增长做出了贡献。人们认为它正在推动 美国拥有几家主要监测公司和各种形式的长期心臟监测的主要参与者，包括 Applied Cardiac Systems (ACS) 和通过收购 Spacelabs 成立的 BioTelemetry。
心臟安全服务市场竞争分析
心臟安全服务市场高度分散，参与者众多。 主要参与者正在使用各种策略，例如新产品发布、扩张、协议、合资企业、合作伙伴关係和收购，以增加他们在这个市场的足迹。 该市场的主要参与者包括 Biotrial、Banook Group、Bioclinica、BioTelemetry、Ncardia AG。
其他福利。
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第一章介绍
- 研究假设和市场定义
- 调查范围
第二章研究方法论
第 3 章执行摘要
第四章市场动态
- 市场概览
- 市场驱动因素
- 心血管疾病患病率增加
- 越来越关注个性化药物的开发
- 製药公司在分析和开发方面的投资增加
- 市场製约因素
- 心臟安全性评估的高成本
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分
- 类型
- 综合服务
- 独立服务
- 服务类型
- 心电图/动态心电图测量
- 血压测量
- 心血管成像
- 深入的 QT 研究
- 最终用户
- 製药和生物製药公司
- 签约研发组织
- 按地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东和非洲
- 海湾合作委员会
- 南非
- 其他中东和非洲地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第六章竞争格局
- 公司简介
- Biotrial
- Bioclinica
- Ncardia AG
- Richmond Pharmacology
- PhysioStim
- BioTelemetry
第7章 市场机会今后动向
The cardiac safety service market is expected to register a CAGR of 9% during the forecast period (2022-2027).
The COVID-19 pandemic has imposed a high burden on the healthcare industry, increasing its focus on providing better healthcare facilities, monitoring devices, services, and teleconsultation. According to the World Health Organization, 2020, more than half (53%) of the countries surveyed have partially or completely disrupted services for hypertension treatment and 31% for cardiovascular emergencies. The emergence of COVID-19 has compelled the government and companies to invest a huge amount of money in research and development to provide better treatments, drugs, and services to patients globally. For instance, it has been found that COVID-19 has increased the risk of all types of cardiovascular ailments. According to the National Center for Biotechnology Information, 2021, evidence of acute cardiac compromise was observed in COVID-19 patients, which includes acute heart failure (3%-33%), myocardial ischemia or infarction (0.9%-11%), and arrhythmias (9%-17%). There has been an increased number of cardiovascular deaths observed in the country during the pandemic. For instance, New York experienced the largest relative increase in deaths due to ischemic heart disease (139%) and hypertensive diseases (164%) during the pandemic, as reported by the American College of Cardiology.
The growth of the cardiac safety service market is mainly due to the rising prevalence of cardiovascular diseases and growing awareness among people regarding cardiac problems and chronic heart diseases. According to the National Center for Biotechnology Information, 2021, around 64.3 million people are suffering from heart failure worldwide. The prevalence rate of heart failure in United States is 6 million, which is 1.8% of its total population. In Canada, the prevalence rate is 1,5% to 1.9%, and in Europe, the prevalence rate of heart failure is estimated to be 1% to 2% in 2021, as reported by the American Heart Association. Additionally, the increasing R&D expenditure by the healthcare industries and outsourcing R&D activities are some factors boosting the growth of the market. Modern technology has brought solutions to help monitor and improve cardiovascular health. For instance, cardiology and radiology equipment now use artificial intelligence and machines, which help by locating potential problems in the heart and blood vessels for the cardiologist to review. The increasing number of cardiovascular diseases among the population tends to increase the use of cardiac safety services in developed countries.
However, the huge cost of services and lack of skilled persons are likely to hinder the market growth.
Cardiac Safety Service Market Trends
The ECG Holter Measurement Service Segment Dominates the Market
The ECG Holter service is expected to dominate the market in the forecast period.
The growth in this segment is mainly attributed to a rise in the geriatric population and the increasing prevalence of cardiovascular diseases. According to the data published by Health System Tracker, 2022, it has been observed that heart disease is the number one leading cause of death in United States. The World Heart Federation has predicted more than 23 million CVD-related deaths per year by 2030. Owing to these factors, there is a need for continuous heart rate monitoring and immediate heartbeat detection devices. ECG monitoring devices have been used in the past years in the healthcare system to detect any abnormality in the functioning of the heart. With the advancement of technology, new ECG Holter measurement devices have been introduced. A Holter monitor is a battery-operated portable ECG device that can be worn by a patient for a duration of 24 to 48 hours and records heart activity (electrocardiogram) continuously and monitors the heart rhythm. This portable device provides several advantages over the traditional ECG devices, such as fewer leads, and the patient is free to move and go around their usual daily routines, which has increased its usage among patients and physicians. Various wearable ECG devices have been introduced in the market that have ECG/EKG sensors to monitor heart health, such as Apple Watch, AliveCor's KardiaBand, and the Withings ScanWatch. The Apple Watch 4 and up and the AliveCor Kardia devices all have been tested and approved by the Food and Drug Administration to detect atrial fibrillation, which is a heart condition that can lead to heart failure, strokes, and even dementia.
These advanced ECG-Holter measurement devices offer a lucrative opportunity for the growth of the cardiac safety services market.
North America Dominates the Market, and It is Expected to do the Same During the Forecast Period
North America is expected to account for a major share of cardiac safety services during the forecast period, owing to the rise in the number of geriatric patients and the high prevalence of cardiovascular diseases. According to the data published by the American Heart Association, 2020, it has been found that approximately 605,000 new heart attack cases and 200,000 recurrent heart attacks have been recorded each year in United States. COVID-19 has increased the risk of heart diseases among people. For instance, US veterans who had COVID-19 faced a 72% higher risk of heart failure after 12 months. According to the data published by Nature Medicine, 2022, titled 'Long Covid' may worsen risk of heart diseases", it has been found that 1.7% of COVID-19 patients in United States are more likely to develop cardiovascular diseases or dysregulated heart rhythm, and 2.39% are likely to have blood clots in the blood vessels.
In addition, the advanced healthcare system, increasing awareness among people of preventive measures for cardiovascular diseases instead of treatment, healthcare campaigns, and government investments in the healthcare system and providing services are likely to boost the growth of the market in the region. There are several leading cardiac event monitoring companies in United States that provide various forms of long-term cardiac monitoring, such as Applied Cardiac Systems (ACS) and BioTelemetry, which are formed from acquisitions of several leading monitoring companies and Spacelabs.
Cardiac Safety Service Market Competitive Analysis
The cardiac safety service market is highly fragmented, with the presence of a large number of players in the market. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the major players of the market include Biotrial, Banook Group, Bioclinica, BioTelemetry, and Ncardia AG.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increase in Prevalence of Cardiovascular Diseases
- 4.2.2 Rising Focus on Developing Personalized Medicines
- 4.2.3 Growth in the Analysis and Development Investment in Pharma
- 4.3 Market Restraints
- 4.3.1 High Cost of Cardiac Safety Evaluation
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 Type
- 5.1.1 Integrated Services
- 5.1.2 Stand-alone Services
- 5.2 Service Type
- 5.2.1 ECG/Holter Measurement
- 5.2.2 Blood Pressure Measurement
- 5.2.3 Cardiovascular Imaging
- 5.2.4 Thorough QT Studies
- 5.3 End User
- 5.3.1 Pharmaceutical and Biopharmaceutical Companies
- 5.3.2 Contract Research Organizations
- 5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Biotrial
- 6.1.2 Bioclinica
- 6.1.3 Ncardia AG
- 6.1.4 Richmond Pharmacology
- 6.1.5 PhysioStim
- 6.1.6 BioTelemetry
